Beat the January sales with these blue-chip bargains

Bilaal Mohamed spots two blue-chip bargains that could post healthy gains in 2017.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The nation’s largest housebuilder Barratt Developments (LSE: BDEV) still hasn’t fully recovered from the post-Brexit sell-off that saw the value of its shares fall to three-year lows in the days following the historic vote to leave the European Union. Many investors will no doubt be wondering whether to take a gamble and buy shares in the FTSE 100 firm at a heavily discounted price or to wait until the effects of Brexit are better understood.

Brexit impact?

Personally I don’t think anyone really knows what the long-term effects of Brexit will actually be, and as the referendum result and Donald Trump victory have shown us, putting too much faith in expert predictions could prove rather foolish. One thing I know is that those investors who took the plunge in June and opted to buy into housebuilding and construction, will no doubt be sure they’ve spotted a bargain in the wake of the post-Brexit vote panic and will just sit back and wait for a long term share price recovery. But were they right and is Barratt the one to back?

In its most recent trading statement the Leicestershire-based housebuilder said that overall market conditions remained healthy with the group trading well since the start of its new financial year, which incidentally began exactly one week after the EU referendum on 1 July.

Economic uncertainty

The board did however acknowledge the potential for economic uncertainty following the vote, but insists that market fundamentals continue to be robust. Barratt’s focus on maintaining good operational and financial performance, and delivering attractive shareholder returns, should help existing shareholders feel a little less insecure. An expected dividend payout of 34.37p per share gives a gigantic 7.3% yield for FY2017, covered 1.5 times by forecast earnings.

Of course Brexit will have increased the risk level for housebuilders such as Barratt. But I believe that with a P/E rating of just nine for the current financial year to June, coupled with that delicious dividend, brave investors could benefit from a significant share price recovery and generous levels of income over the longer term.

Ageing societies

Barratt Developments isn’t the only blue-chip firm on sale this January. Private hospital group Mediclinic International (LSE: MDC) has also caught my eye so far in 2017, and I believe there could be significant upside potential for investors willing to dip a toe into one of the lesser-known businesses in the FTSE 100. I expect to see Mediclinic do well in the coming years with ageing societies, favourable demographics and rising incomes in its chosen markets helping to drive growth in the years ahead.

Shares in the South Africa headquartered business trade on an expensive-looking P/E ratio of 20 for the current year to March, but this falls to a more reasonable 17 for fiscal 2018 after an anticipated 20% rise in underlying profits. Recent share price weakness means the shares are trading at a 30% discount to summer 2016 levels, and now could be the perfect time to grab a slice of this growing international healthcare provider.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »